NMDA antagonist (IC50
= 11 μ
M for inhibition of [3
H]MK-801 binding to rat forebrain membranes). Protects against NMDA- and quisqualate-induced neurotoxicity (EC50
= 3.8 μ
M) and enhances dopamine D1
receptor activity. Inhibits NF-κ
B, reducing TNF-α
, IL-6 and nitric oxide production, and acts as a free radical scavenger. Exhibits beneficial effects in experimental models of multiple sclerosis, bacterial meningitis, septic shock, epilepsy, and traumatic and ischemic brain injury. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture.
Eshhar et al.
Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system.
Striem et al.
Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid.
Gallily et al.
The cannabinoid dexanabinol is an inhibitor of the nuclear factor kappa B (NF-κB).
Juttler et al.